PCI治疗老年冠心病应用瑞舒伐他汀辅以替格瑞洛对其心功能和血脂水平的影响

张启杰; 鄢高亮

PCI治疗老年冠心病应用瑞舒伐他汀辅以替格瑞洛对其心功能和血脂水平的影响

The Influence of Clinical Effect, Cardiac function and Lipid Level Using Resuvastatin and Tigrelol for Coronary Heart Disease Who Treated by Percutaneous Coronary Intervention

摘要

摘要: 目的分析经皮冠状动脉介入（PCI）治疗老年冠心病开展瑞舒伐他汀辅以替格瑞洛治疗对其临床效果、心功能和血脂水平的影响。方法选取2016年1月至2018年3月于我院就诊并接受冠状动脉支架植入术的老年冠心病患者128例。按入院先后顺序随机均分为观察组和对照组，每组64例，开展前瞻性随机对照研究。入院后所有患者均给予基础治疗，此外对照组术前口服瑞舒伐他汀+拜阿司匹林+氯吡格雷治疗，观察组术前口服瑞舒伐他汀+拜阿司匹林+替格瑞洛治疗，两组均持续用药6个月。比较两组血脂水平、再狭窄率、心功能指标及血小板聚集功能，并记录不良心血管事件的发生情况。结果 PCI治疗后6月显示两组TC、TG、LDL-C均较治疗前显著降低（均P<0.05），而HDL-C较治疗前显著升高(P<0. 05)，组间比较差异无统计学意义（均P>0.05），对照组发生2例再狭窄，观察组发生1例再狭窄，组间比较不存在显著性差异(P>0. 05)；治疗后两组T-proBNP均较治疗前明显降低（均P<0.05），与对照组比较，观察组降低更明显（P<0.05）；PCI治疗后6月显示两组血小板最大聚集率均较治疗前显著降低（均P<0.05），与同期对照组比较，观察组降低更明显(P<0.05)；观察组心血管不良事件的总发生率明显低于对照组（P <0.05）。结论 PCI治疗老年冠心病开展瑞舒伐他汀辅以替格瑞洛治疗可有效减少在狭窄的发生率，改善血脂和心功能，提高抗血小板聚集作用，安全性较高。

Abstract: Objective To analyzehe influence of clinical effect, cardiac function and lipid level using resuvastatin and tigrelol for coronary heart disease who treated by percutaneous coronary intervention. Method Selected 128 patients with coronary heart disease, who were treated by coronary stent implantation in our hospital between Fanuary 2016 to March 2018. According to the order of admission, all patients were randomly divided into observation group and control group, with 64 cases in each group, and a prospective randomized control study was conducted. All patients were given basic treatment after admission. In addition, the control group received oral resuvastatin + biaspirin + clopidogrel treatment before surgery, while the observation group received oral resuvastatin + biaspirin + tigrelol treatment before surgery, and both groups were continuously treated with resuvastatin for 6 months. Blood lipid level, restenosis rate, cardiac function index and platelet aggregation function were compared between the two groups, and adverse cardiovascular events were recorded. Results Six months after PCI treatment, TC, TG and LDL-C in the two groups were significantly lower than before treatment (all P<0.05), while HDL-C was significantly higher than before treatment (P< 0.05), and that was no statistically significant difference between the two groups (all P>0.05); There were 2 cases of restenosis in the control group and 1 case of restenosis in the observation group. and that was no significant difference between the two groups (P>0. 05); After treatment, T-proBNP in both groups was significantly lower than before treatment (all P<0.05), compared with the control group, the observation group was significantly lower (P<0.05); Six months after PCI treatment, the maximum platelet aggregation rate in both groups was significantly lower than that before treatment (all P<0.05), and compared with the control group in the same period, the maximum platelet aggregation rate in the observation group was significantly lower (P<0.05); The total incidence of adverse cardiovascular events in the observation group was significantly lower than that in the control group (P <0.05). Conclusion The treatment of coronary heart disease by PCI with resuvastatin and tigrelol can effectively reduce the incidence of stenosis, improve the blood lipid and heart function, improve the anti-platelet aggregation, and have a high safety

HTML全文

参考文献(0)

施引文献

资源附件(0)